首页> 外文期刊>Journal of Hepatology: The Journal of the European Association for the Study of the Liver >Treatment of acetaminophen-induced acute liver failure in the mouse with conditionally immortalized human hepatocytes.
【24h】

Treatment of acetaminophen-induced acute liver failure in the mouse with conditionally immortalized human hepatocytes.

机译:有条件永生化人类肝细胞治疗对乙酰氨基酚诱导的小鼠急性肝衰竭。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

BACKGROUND/AIMS: Liver failure is a life threatening condition currently treated by palliative measures and, when applicable, organ transplantation. The use of a bioartificial organ capable of fulfilling the main functions of the liver would represent an attractive alternative. However, the shortage of suitable donor cells, and their limited growth ability have impeded the development of this strategy. We investigated whether lentiviral vectors allow for conditional immortalization of human hepatocytes and whether these immortalized hepatocytes could reverse lethal acute liver failure. METHODS: We exposed primary human hepatocytes to Cre-excisable lentiviral vectors coding for SV40T Antigen, telomerase, and/or Bmi-1 and tested the functionality of the resulting cell lines. Therapeutic potential of immortalized hepatocytes were tested in a murine model of acetaminophen-induced hepatic injury. RESULTS: The immortalized hepatocytes grew continuously yet were non-tumorigenic, stopped proliferating when exposed to Cre recombinase, and conserved defining properties of primary hepatocytes, including the ability to secrete liver-specific proteins and to detoxify drugs. The implantation of encapsulated immortalized human hepatocytes rescued mice from lethal doses of acetaminophen. CONCLUSIONS: Lentiviral vectors represent tools of choice for immortalization of non-dividing primary cells, and lentivirally immortalized human hepatocytes are promising reagents for cell-based therapy of acute liver failure.
机译:背景/目的:肝衰竭是目前威胁生命的疾病,目前通过姑息治疗和器官移植来治疗。使用能够完成肝脏主要功能的生物人工器官将代表一种有吸引力的选择。然而,合适的供体细胞的缺乏及其有限的生长能力阻碍了该策略的发展。我们调查了慢病毒载体是否允许人类肝细胞有条件永生,以及这些永生肝细胞是否可以逆转致命的急性肝衰竭。方法:我们将人类原代肝细胞暴露于可编码Cre的慢病毒载体中,该载体编码SV40T抗原,端粒酶和/或Bmi-1,并测试了所得细胞系的功能。在对乙酰氨基酚诱发的肝损伤的小鼠模型中测试了永生化肝细胞的治疗潜力。结果:永生化的肝细胞持续增长,但没有致瘤性,当暴露于Cre重组酶时停止增殖,并且保留了原代肝细胞的定义特性,包括分泌肝特异性蛋白和排毒的能力。封装的永生化人类肝细胞的移植从致死剂量的对乙酰氨基酚中拯救了小鼠。结论:慢病毒载体代表了永生不分裂原代细胞的选择工具,而慢病毒永生化的人肝细胞是用于基于细胞的急性肝衰竭治疗的有前途的试剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号